MarketBeat
18 Nov 2026, 02:13 UTC · 1h ago
GSK CFO Points to Cancer Drugs to Bridge £3.4 Billion Sales Forecast Gap
Impact · against what's priced in
GSK signals a bullish discrepancy between its internal 2031 sales targets (£40B+) and analyst consensus (£36.6B), primarily driven by an aggressive ramp-up in oncology Phase III trials. While cost-cutting and cash flow are steady, the significant increase in late-stage pipeline activity provides a potential catalyst for revenue revisions.
- GSK+0.50
No priced-in read yet
- In context
The company's target of £40 billion in annual sales by 2031 creates a £3.4 billion gap above the current analyst consensus of £36.6 billion, supported by a jump to 22 Phase III trial starts this year from seven last year.
Read from the article alone





